MX2008016520A - Medicamentos. - Google Patents

Medicamentos.

Info

Publication number
MX2008016520A
MX2008016520A MX2008016520A MX2008016520A MX2008016520A MX 2008016520 A MX2008016520 A MX 2008016520A MX 2008016520 A MX2008016520 A MX 2008016520A MX 2008016520 A MX2008016520 A MX 2008016520A MX 2008016520 A MX2008016520 A MX 2008016520A
Authority
MX
Mexico
Prior art keywords
wnt5a
therapeutically effective
scarring
medicament
derivative
Prior art date
Application number
MX2008016520A
Other languages
English (en)
Spanish (es)
Inventor
Mark William James Ferguson
Hugh Gerard Laverty
Nicholas Occleston
Sharon O'kane
Kerry Nield
Nicholas Goldspink
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of MX2008016520A publication Critical patent/MX2008016520A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2008016520A 2006-06-30 2007-06-29 Medicamentos. MX2008016520A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0613031.4A GB0613031D0 (en) 2006-06-30 2006-06-30 Medicaments
PCT/GB2007/002445 WO2008001113A2 (en) 2006-06-30 2007-06-29 Use of wnt5a for inhibiting scarring

Publications (1)

Publication Number Publication Date
MX2008016520A true MX2008016520A (es) 2009-04-01

Family

ID=36888398

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008016520A MX2008016520A (es) 2006-06-30 2007-06-29 Medicamentos.

Country Status (11)

Country Link
US (1) US20100137201A1 (OSRAM)
EP (1) EP2046364A2 (OSRAM)
JP (1) JP2009542609A (OSRAM)
CN (1) CN101511383A (OSRAM)
AU (1) AU2007263593A1 (OSRAM)
BR (1) BRPI0713807A2 (OSRAM)
CA (1) CA2656965A1 (OSRAM)
GB (1) GB0613031D0 (OSRAM)
MX (1) MX2008016520A (OSRAM)
WO (1) WO2008001113A2 (OSRAM)
ZA (1) ZA200900708B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0702930D0 (en) * 2007-02-15 2007-03-28 Renovo Ltd Medicaments and methods for inhibition of scarring
WO2009047330A1 (en) * 2007-10-12 2009-04-16 Universite Louis Pasteur Use of wnt5a for treating or preventing obesity and atherosclerosis
CN101790221B (zh) * 2009-01-22 2015-05-06 中兴通讯股份有限公司 家用基站切换时网络接入控制方法及系统
EP2226080A1 (en) * 2009-03-05 2010-09-08 Universiteit Maastricht Antagonistic peptides for frizzled-1 and frizzled-2
JP7299889B2 (ja) * 2017-08-20 2023-06-28 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア 緑内障を治療するためのＷｎｔ５ａの調節

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485972B1 (en) * 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
CA2408701A1 (en) * 2000-05-12 2001-11-22 University Of Utah Research Foundation Compositions and methods for tissue dedifferentiation and regeneration
US20040087016A1 (en) * 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
JP2004533829A (ja) * 2001-04-06 2004-11-11 インサイト・ゲノミックス・インコーポレイテッド 細胞成長、分化および細胞死関連タンパク質
US20050037011A1 (en) * 2002-11-21 2005-02-17 Jones Stephen N. Diagnosing and treating hematopoietic cancers
US7374760B2 (en) * 2003-05-15 2008-05-20 The University Of Chicago Methods and compositions for nerve regeneration
WO2005118782A2 (en) * 2004-04-16 2005-12-15 Hydra Biosciences, Inc. Methods of promoting cardiac cell proliferation
EP2322600B1 (en) * 2004-08-30 2012-03-21 Theregen, Inc. Cultured three dimensional tissues and uses thereof

Also Published As

Publication number Publication date
WO2008001113A2 (en) 2008-01-03
CN101511383A (zh) 2009-08-19
EP2046364A2 (en) 2009-04-15
WO2008001113A3 (en) 2008-03-13
US20100137201A1 (en) 2010-06-03
GB0613031D0 (en) 2006-08-09
CA2656965A1 (en) 2008-01-03
AU2007263593A1 (en) 2008-01-03
BRPI0713807A2 (pt) 2012-11-06
ZA200900708B (en) 2010-05-26
JP2009542609A (ja) 2009-12-03

Similar Documents

Publication Publication Date Title
NZ572049A (en) Method for treatment of constipation-predominant irritable bowel syndrome
WO2008024439A3 (en) 4-aminoquinazoline derivatives and methods of use thereof
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
TN2009000224A1 (en) Inhibitors of akt activity
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2010065662A3 (en) Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
MX2009002893A (es) Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
WO2009074827A3 (en) Combination comprising a mek inhibitor and an aurora kinase inhibitor
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
MX2015005798A (es) Terapia de combinacion.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2009140269A3 (en) Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
MX2011008944A (es) Tratamiento de trastornos relacionados con la discinesia.
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
WO2010022236A3 (en) Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
MX2008016520A (es) Medicamentos.
MX2011011687A (es) Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer.
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
WO2008077062A3 (en) Suppression of stat3 reactivation after src kinase inhibition to treat cancer
CA2632207C (en) Use of calcitonin for the treatment of ra
WO2006068796A3 (en) Inhibitors of akt activity
WO2011060253A3 (en) Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms

Legal Events

Date Code Title Description
FA Abandonment or withdrawal